Teva Pharmaceutical Industries Ltd Company Profile (NYSE:TEVA)

About Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Ltd logoTeva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules. Its central nervous system (CNS) portfolio includes Copaxone for the treatment of multiple sclerosis, Azilect for the treatment of the symptoms of Parkinson's disease and Nuvigil for the treatment of sleep disorders, as well as several therapies for the treatment of pain care. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo in the United States and Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio outside the United States. Its women's health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: TEVA
  • CUSIP:
Key Metrics:
  • Previous Close: $51.55
  • 50 Day Moving Average: $53.53
  • 200 Day Moving Average: $53.95
  • Trailing P/E Ratio: 34.44
  • Foreward P/E Ratio: 8.68
  • P/E Growth: 1.88
  • Market Cap: $47.12B
  • Outstanding Shares: 914,000,000
  • Beta: 0.82
Additional Links:
Companies Related to Teva Pharmaceutical Industries Ltd:

Analyst Ratings

Consensus Ratings for Teva Pharmaceutical Industries Ltd (NYSE:TEVA) (?)
Ratings Breakdown: 6 Hold Ratings, 18 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $68.30 (32.49% upside)

Analysts' Ratings History for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Show:
DateFirmActionRatingPrice TargetDetails
8/25/2016MizuhoReiterated RatingBuy$70.00 -> $64.00View Rating Details
8/25/2016Credit Suisse Group AGReiterated RatingNeutral$59.00 -> $51.63View Rating Details
8/16/2016Leerink SwannReiterated RatingOutperform$66.00View Rating Details
8/15/2016GuggenheimReiterated RatingBuy$80.00View Rating Details
8/8/2016Piper Jaffray Cos.Reiterated RatingNeutral$55.00 -> $57.00View Rating Details
8/5/2016Oppenheimer Holdings Inc.DowngradeOutperform -> Market Perform$70.29View Rating Details
8/3/2016Jefferies GroupReiterated RatingBuyView Rating Details
7/26/2016JPMorgan Chase & Co.Reiterated RatingOverweight$75.00View Rating Details
7/20/2016RBC Capital MarketsReiterated RatingOutperform$71.00View Rating Details
7/18/2016Maxim GroupReiterated RatingBuyView Rating Details
7/18/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details
7/18/2016HSBCUpgradeHold -> BuyView Rating Details
7/17/2016Goldman Sachs Group Inc.Lower Price Target$70.00 -> $60.00View Rating Details
6/13/2016Citigroup Inc.Reiterated RatingBuy$75.00View Rating Details
6/10/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details
5/10/2016Deutsche Bank AGLower Price TargetBuy$80.00 -> $71.00View Rating Details
5/3/2016Morgan StanleyReiterated RatingOverweight$71.00 -> $69.00View Rating Details
4/19/2016Canaccord GenuityReiterated RatingBuyView Rating Details
4/12/2016Bank of America Corp.Reiterated RatingBuy$82.00View Rating Details
4/7/2016BTIG ResearchReiterated RatingBuy$77.00View Rating Details
3/31/2016Sanford C. BernsteinReiterated RatingOutperform$43.00 -> $50.00View Rating Details
3/2/2016NomuraReiterated RatingNeutral$73.00View Rating Details
2/21/2016ArgusReiterated RatingBuy$82.00 -> $75.00View Rating Details
11/27/2015Berenberg BankLower Price TargetHold$72.00 -> $65.00View Rating Details
7/28/2015BMO Capital MarketsUpgradeMarket Perform -> Outperform$75.00 -> $80.00View Rating Details
7/27/2015Standpoint ResearchBoost Price TargetBuy$78.00 -> $84.00View Rating Details
6/3/2015Raymond James Financial Inc.Initiated CoverageMarket PerformView Rating Details
5/2/2015Cowen and CompanyReiterated RatingOutperform$100.00View Rating Details
4/24/2015GabelliReiterated RatingBuyView Rating Details
4/7/2015Barclays PLCBoost Price TargetOverweight$70.00 -> $75.00View Rating Details
3/31/2015CRT CapitalBoost Price TargetBuy$67.00 -> $70.00View Rating Details
1/20/2015Sterne Agee CRTSet Price TargetBuy$65.00View Rating Details
10/8/2014ING GroupInitiated CoveragePositiveView Rating Details
9/4/2014Evercore ISIInitiated CoverageBuyView Rating Details
(Data available from 8/28/2014 forward)

Earnings

Earnings History for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216$1.20$1.25$4.86 billion$5.00 billionViewN/AView Earnings Details
5/9/2016Q116$1.17$1.20$4.78 billion$4.81 billionViewN/AView Earnings Details
2/11/2016Q415$1.29$1.28$4.83 billion$4.88 billionViewListenView Earnings Details
10/29/2015Q315$1.28$1.35$4.75 billion$4.80 billionViewListenView Earnings Details
7/30/2015Q215$1.31$1.43$4.90 billion$4.97 billionViewListenView Earnings Details
4/30/2015Q115$1.26$1.36$4.84 billion$5.00 billionViewN/AView Earnings Details
2/5/2015Q414$1.31$1.31$5.17 billion$5.17 billionViewN/AView Earnings Details
10/30/2014Q314$1.23$1.32$5.09 billion$5.06 billionViewN/AView Earnings Details
7/31/2014Q214$1.21$1.23$5.08 billion$5.00 billionViewN/AView Earnings Details
5/1/2014Q114$1.22$1.22$5.11 million$5.00 billionViewN/AView Earnings Details
2/6/2014Q413$1.26$1.42$5.19 billion$5.40 billionViewN/AView Earnings Details
10/31/2013Q313$1.26$1.27$5.00 billion$5.06 billionViewN/AView Earnings Details
8/1/2013Q213$1.20$1.20$4.94 billion$4.90 billionViewN/AView Earnings Details
5/2/2013Q113$1.10$1.12$4.85 billion$4.90 billionViewN/AView Earnings Details
2/7/2013Q412$1.33$1.32$5.26 billion$5.20 billionViewN/AView Earnings Details
11/1/2012Q312$1.25$1.28$5.08 billion$5.00 billionViewN/AView Earnings Details
8/2/2012$1.28$1.28ViewN/AView Earnings Details
5/9/2012$1.44$1.47ViewN/AView Earnings Details
2/15/2012$1.58$1.59ViewN/AView Earnings Details
11/2/2011$1.22$1.25ViewN/AView Earnings Details
7/27/2011$1.08$1.10ViewN/AView Earnings Details
5/11/2011$1.03$1.04ViewN/AView Earnings Details
2/8/2011$1.28$1.25ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Current Year EPS Consensus Estimate: $5.27 EPS
Next Year EPS Consensus Estimate: $5.94 EPS

Dividends

Current Dividend Information for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Annual Dividend:$1.16
Dividend Yield:2.25%
Payout Ratio:22.01% (Based on Current Year Consensus EPS Estimate)
19.53% (Based on Next Year Consensus EPS Estimate)
Dividend Growth:13.00% (3 Year Average)

Dividend History for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/4/2016quarterly$0.348/18/20168/22/20169/8/2016
5/9/2016quarterly$0.345/20/20165/24/20166/7/2016
2/16/2016Quarterly$0.292/25/20162/29/20163/14/2016
10/29/2015quarterly$0.3411/13/201511/17/201512/3/2015
7/30/2015quarterly$0.348/18/20158/20/20159/3/2015
5/5/2015special$0.342.25%5/15/20155/19/20156/4/2015
2/5/2015quarterly$0.342.36%2/17/20152/19/20153/3/2015
10/31/2014special$0.322.43%11/13/201411/17/201412/2/2014
8/1/2014quarterly$0.352.61%8/19/20148/21/20149/4/2014
5/2/2014quarterly$0.352.77%5/16/20145/20/20146/2/2014
2/4/2014$0.342/20/20142/24/20143/10/2014
11/1/2013quarterly$0.333.51%11/18/201311/20/201312/2/2013
8/5/2013quarterly$0.323.34%8/16/20138/20/20139/3/2013
8/1/2013quarterly$0.328/20/20139/2/2013
5/6/2013special$0.323.28%5/16/20135/20/20136/3/2013
2/8/2013quarterly$0.313.21%2/19/20132/21/20133/7/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
DateHeadline
News IconTEVA: PTAB Invalidates Two Patents; Copaxone Generics Unlikely in and#039;17 (NYSE:TEVA)
mrtopstep.com - August 27 at 6:50 PM
bidnessetc.com logoTeva Pharmaceutical Industries Ltd: PTAB Invalidates Two Patents; Copaxone Generics Unlikely in '17 - Bidness ETC (NYSE:TEVA)
www.bidnessetc.com - August 27 at 6:50 PM
thecountrycaller.com logoTeva Pharmaceutical (TEVA): Analyst Cuts PT to $64; Still Sees 25% Upside Potential (NYSE:TEVA)
www.thecountrycaller.com - August 26 at 7:25 PM
thestreet.com logoFTC spells out new concerns over generic drug mergers (NYSE:TEVA)
www.thestreet.com - August 26 at 7:25 PM
thecountrycaller.com logoTeva Pharmaceutical (TEVA): Analyst Cuts PT to $64; Still Sees 25% Upside Potential - TCC (NYSE:TEVA)
www.thecountrycaller.com - August 26 at 10:39 AM
marketrealist.com logoAbbVie Expects Investigational Drug Elagolix to Be a Blockbuster (NYSE:TEVA)
marketrealist.com - August 26 at 10:39 AM
bloomberg.com logoTeva Plunges After Two U.S. Copaxone Patents Invalidated (NYSE:TEVA)
www.bloomberg.com - August 25 at 8:00 PM
News IconTeva loses on 40mg Copaxone (for MS) at PTAB (NYSE:TEVA)
ipbiz.blogspot.com - August 25 at 8:00 PM
News IconEye On Earnings: Teva Pharmaceutical Industries Limited (NYSE:TEVA) (NYSE:TEVA)
larampadinapoli.com - August 25 at 8:00 PM
4-traders.com logoTeva Pharmaceutical Industries : US board invalidates Copaxone double-dose patents (NYSE:TEVA)
www.4-traders.com - August 25 at 8:00 PM
schaeffersresearch.com logoAnalyst Downgrades: Amgen, Inc., Teva Pharmaceutical Industries Ltd, and HP Inc (NYSE:TEVA)
www.schaeffersresearch.com - August 25 at 8:00 PM
thecountrycaller.com logoWill Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Survive Its Patent Invalidation? (NYSE:TEVA)
www.thecountrycaller.com - August 25 at 8:00 PM
News IconLeading stocks in today’s market: Teva Pharmaceutical Industries Limited (NYSE:TEVA) (NYSE:TEVA)
twincountynews.com - August 25 at 8:00 PM
marketrealist.com logoUS Patent and Trademark Office Invalidates Two Copaxone 40 Patents (NYSE:TEVA)
marketrealist.com - August 25 at 8:00 PM
wsj.com logoMylan's EpiPen Price Increases Highlight Its Grip on the Market (NYSE:TEVA)
www.wsj.com - August 25 at 8:00 PM
News IconDrug-Makers Detain Active Momentum- Pfizer Inc. (NYSE:PFE), Teva Pharmaceutical Industries (NYSE:TEVA) - Seneca Globe (NYSE:TEVA)
www.senecaglobe.com - August 25 at 10:17 AM
marketrealist.com logoWill Teva Pharmaceutical Strengthen Specialty Pipeline in 3Q16? (NYSE:TEVA)
marketrealist.com - August 25 at 10:17 AM
thestreet.com logoTeva Stock Gains, Leerink: Despite Patent Loss, No Generic Competition Until 2018 (NYSE:TEVA)
www.thestreet.com - August 25 at 10:17 AM
reuters.com logoBRIEF-Teva confirms PTAB's decisions on two patents in IPR challenge to Copaxone (NYSE:TEVA)
www.reuters.com - August 24 at 7:31 PM
streetinsider.com logoTeva Pharma (TEVA) to Appeal PTAB's Decisions on Two COPAXONE Patents (NYSE:TEVA)
www.streetinsider.com - August 24 at 7:31 PM
bloomberg.com logoTeva Plunges After Two U.S. Copaxone Patents Invalidated (3) (NYSE:TEVA)
washpost.bloomberg.com - August 24 at 7:31 PM
News IconTeva Confirms PTABs Decisions on Two Patents in IPR Challenge to COPAXONE® 40 mg (NYSE:TEVA)
business.itbusinessnet.com - August 24 at 7:31 PM
4-traders.com logoTeva Pharmaceutical Industries : Confirms PTAB’s Decisions on Two Patents in IPR Challenge to COPAXONE® 40 mg (NYSE:TEVA)
www.4-traders.com - August 24 at 7:31 PM
News IconTeva Pharmaceutical Industries Limited (NYSE:TEVA) from Drug Manufacturers – Other – Todays Top Gains (NYSE:TEVA)
twincountynews.com - August 24 at 7:31 PM
News IconExperts Analysis on Price Reaction History: Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) - Post Registrar (NYSE:TEVA)
postregistrar.com - August 24 at 7:31 PM
marketrealist.com logoDespite Litigation, Teva’s Copaxone Could See Robust 2016 Revenue (NYSE:TEVA)
marketrealist.com - August 24 at 10:49 AM
marketrealist.com logoPerformance of AstraZeneca’s Growth Platforms in 2Q16 (NYSE:TEVA)
marketrealist.com - August 23 at 7:54 PM
News IconTeva Canada Innovation Announces Approval of Three-Times-a-Week COPAXONE® 40mg/mL by Health Canada (NYSE:TEVA)
www.itbusinessnet.com - August 23 at 12:14 PM
thestreet.com logoA Backlash Materializes Against Soaring EpiPen Prices (NYSE:TEVA)
www.thestreet.com - August 23 at 12:14 PM
News IconStocks Alert: Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA), 58.com Inc (ADR)(NYSE:WUBA) - NYSE Journal (press release) (NYSE:TEVA)
stockznews.com - August 22 at 10:28 AM
News IconMomentum Stocks in Focus: Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), Rock Creek Pharmaceuticals Inc ... - Post Registrar (NYSE:TEVA)
postregistrar.com - August 22 at 10:28 AM
marketrealist.com logoCan Allergan Generics Boost Teva Pharmaceutical’s 2016 Revenues? (NYSE:TEVA)
marketrealist.com - August 22 at 10:28 AM
4-traders.com logoTEVA PHARMACEUTICAL INDUSTRIES LIMITED : ex-dividend day for interim dividend (NYSE:TEVA)
www.4-traders.com - August 21 at 6:48 PM
News IconIs it Time to Buy Teva Pharmaceutical Industries Limited (NYSE:TEVA)? The Consensus Is In - Post News (NYSE:TEVA)
www.kentuckypostnews.com - August 20 at 7:16 PM
News IconTeva Pharma's Cinqaero receives European marketing approval (NYSE:TEVA)
www.bioportfolio.com - August 20 at 11:44 AM
News IconDrug Manufacturers – Other: Teva Pharmaceutical Industries Limited (NYSE:TEVA) Position of the day (NYSE:TEVA)
twincountynews.com - August 19 at 7:39 PM
News IconScorching Healthcare Stocks in Action- Immunomedics (NASDAQ ... - Seneca Globe (NYSE:TEVA)
www.senecaglobe.com - August 19 at 7:39 PM
zacks.com logoTeva Cinqaero Gets EU Nod for Severe Eosinophilic Asthma (NYSE:TEVA)
www.zacks.com - August 19 at 10:44 AM
4-traders.com logoTeva Pharmaceutical Industries : Announces Launch of Generic Gleevec® Tablets in the United States (NYSE:TEVA)
www.4-traders.com - August 19 at 10:44 AM
News IconSell-side & Crowd View on Teva Pharmaceutical Industries Limited (NYSE:TEVA) - Post News (NYSE:TEVA)
www.kentuckypostnews.com - August 18 at 8:00 PM
seekingalpha.com logoTeva's Cinqaero OK'd in Europe - Teva Pharmaceutical Industries ... - Seeking Alpha (NYSE:TEVA)
seekingalpha.com - August 18 at 8:00 PM
4-traders.com logoTeva Pharmaceutical Industries : European Commission Grants Marketing Authorization for Teva’s CINQAERO® (reslizumab) (NYSE:TEVA)
www.4-traders.com - August 18 at 10:50 AM
finance.yahoo.com logo3:59 am Teva Pharma receives Marketing Authorization in EU for CINQAERO (NYSE:TEVA)
finance.yahoo.com - August 18 at 10:50 AM
News IconStock's Report of the Monday - Teva Pharmaceutical Industries Limited's (TEVA) (NYSE:TEVA)
crcconnection.com - August 17 at 8:05 PM
News IconRevenue Estimates Analysis of: Teva Pharmaceutical Industries Limited (NYSE:TEVA) (NYSE:TEVA)
myhealthbowl.com - August 17 at 8:05 PM
News IconLarge Cap Drug Manufacturers – Other: Teva Pharmaceutical Industries Limited (NYSE:TEVA) (NYSE:TEVA)
twincountynews.com - August 17 at 8:05 PM
News IconTop Gainers of the Day: Teva Pharmaceutical Industries Limited (NYSE:TEVA) from Drug Manufacturers – Other (NYSE:TEVA)
twincountynews.com - August 17 at 10:44 AM
bloomberg.com logoTeva Chief Seeks Growth Beyond $40.5 Billion Allergan Deal (1) (NYSE:TEVA)
washpost.bloomberg.com - August 16 at 7:51 PM
barrons.com logo[$$] Lilly and Allergan Are Large-Cap Pharma Picks (NYSE:TEVA)
www.barrons.com - August 16 at 7:51 PM
thecountrycaller.com logoWhat's Ahead for Teva Pharmaceutical Industries Ltd (ADR) (TEVA): AGN Deal, Copaxone Decision - TCC (NYSE:TEVA)
www.thecountrycaller.com - August 15 at 8:06 PM

Social

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) Chart for Sunday, August, 28, 2016


Last Updated on 8/28/2016 by MarketBeat.com Staff